Copyright
©The Author(s) 2016.
World J Diabetes. Jun 10, 2016; 7(11): 230-238
Published online Jun 10, 2016. doi: 10.4239/wjd.v7.i11.230
Published online Jun 10, 2016. doi: 10.4239/wjd.v7.i11.230
Active GLP-1 low (n = 26) | Active GLP-1 mid (n = 25) | Active GLP-1 high (n = 25) | P value | |
Sex male/female (%) | 82 | 88 | 88 | |
Age (yr) | 60.5 ± 13.7 | 63.8 ± 10.8 | 58.5 ± 15.3 | |
Disease duration (yr) | 16.2 ± 11.2 | 15.5 ± 10.8 | 12.7 ± 10.4 | |
FPG (mg/dL) | 161.1 ± 35.4 | 160.1 ± 41.6 | 160.7 ± 45.3 | |
HbA1c (%) | 7.43 ± 1.18 | 7.44 ± 0.66 | 7.61 ± 1.32 | |
BMI (kg/m2) | 22.3 ± 5.8 | 24.1 ± 10.7 | 26.8 ± 5.6 | 1 |
Sulfonylurea (%) | 54 | 52 | 57 | |
Biguanide (%) | 45 | 52 | 76 | |
Systolic BP (mmHg) | 126.8 ± 17.5 | 133.9 ± 15.1 | 129.2 ± 17.8 | |
Diastolic BP (mmHg) | 74.5 ± 10.8 | 76.8 ± 13.6 | 78.0 ± 12.2 | |
Proteinuria | 8 | 22 | 21 | |
γGTP (IU/L) | 38.5 ± 34.3 | 45.9 ± 35.5 | 43.3 ± 27.5 | |
AST (IU/L) | 28.3 ± 34.0 | 22.9 ± 8.2 | 25.0 ± 10.0 | |
ALT (IU/L) | 36.0 ± 60.1 | 23.9 ± 15.8 | 32.2 ± 21.3 | |
TC (mg/dL) | 193.3 ± 29.6 | 214.3 ± 32.0 | 189.1 ± 26.0 | |
HDLC (mg/dL) | 57.0 ± 16.9 | 61.6 ± 16.0 | 51.9 ± 14.3 | |
TG (mg/dL) | 127.1 ± 66.3 | 133.4 ± 132.0 | 135.1 ± 68.5 | |
LDLC (mg/dL) | 109.8 ± 26.9 | 122.4 ± 36.5 | 110.0 ± 24.5 | |
UA (mg/dL) | 4.87 ± 0.98 | 5.22 ± 1.09 | 5.65 ± 1.27 | 1 |
Cr (mg/dL) | 0.83 ± 0.23 | 0.77 ± 0.15 | 0.75 ± 0.16 | |
eGFR (mL/min) | 76.7 ± 21.3 | 78.8 ± 17.7 | 83.1 ± 19.3 |
Variables | Univariate | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | ||||||
OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | OR (95%CI) | P value | |
GLP-1 not high group | 4.50 (1.40-17.6) | 0.01 | 5.72 (1.64-25.99) | 0.01 | 4.93 (1.07-32.96) | 0.04 | 7.66 (1.48-57.48) | 0.01 | 8.04 (1.30-75.83) | 0.02 | 5.83 (1.12-45.6) | 0.04 |
HbA1c (%) | 1.81 (1.32-2.6) | 0.001 | 1.69 (1.03-3.02) | 0.04 | 2.30 (1.11-5.63) | 0.02 | 2.23 (1.02-5.59) | 0.05 | 2.63 (1.19-6.88) | 0.02 | 2.51 (1.04-7.05) | 0.04 |
FPG (mg/dL) | 1.01 (1.00-1.02) | 0.003 | ||||||||||
Sex (male) | 1.85 (0.73-4.65) | 0.19 | 5.69 (0.73-57.54) | 0.1 | 4.39 (0.51-47.1) | 0.18 | 5.53 (0.46-92.72) | 0.18 | 6.97 (0.78-90.5) | 0.08 | ||
Age (yr) | 1.00 (0.97-1.02) | 0.77 | 0.98 (0.91-1.05) | 0.53 | 0.96 (0.88-1.03) | 0.26 | 0.99 (0.92-1.08) | 0.89 | 0.97 (0.90-1.05) | 0.48 | ||
Duration (yr) | 1.03 (1.00-1.07) | 0.09 | 1.01 (0.95-1.09) | 0.73 | 1.01 (0.94-1.09) | 0.77 | 1.03 (0.95-1.13) | 0.44 | 0.67 | |||
BMI (kg/m2) | 0.92 (0.83-0.99) | 0.05 | 0.70 (0.50-0.91) | 0.003 | 0.64 (0.43-0.86) | 0.001 | 0.63 (0.39-0.90) | 0.01 | 0.66 (0.43-0.92) | 0.01 | ||
Sulfonylurea (+) | 1.25 (0.63-2.46) | 0.53 | 1.15 (0.22-6.13) | 0.87 | ||||||||
Biguanide (+) | 2.83 (1.42-5.76) | 0.003 | 0.18 (0.02-1.01) | 0.05 | ||||||||
Plasma insulin (μU/mL) | 0.9 (0.82-0.98) | 0.01 | 1.25 (0.94-1.69] | 0.12 | ||||||||
C peptide (ng/mL) | 0.8 (0.55-1.11) | 0.19 | ||||||||||
PI/IRI | 1.33 (0.78-2.6) | 0.29 | 4.94 (0.54-99.3) | 0.17 | ||||||||
Glcagon (pg/mL) | 0.99 (0.97-1.00) | 0.11 | 0.97 (0.18-4.63) | 0.97 | ||||||||
Log (hsCRP) [log (mg/mL)] | 1.03 (0.53-1.98) | 0.92 | 0.98 (0.94-1.01) | 0.21 | ||||||||
HOMA-β | 0.97 (0.95-0.99) | 0.01 | 1.02 (0.94-1.09) | 0.67 | ||||||||
HOMA-IR | 0.83 (0.67-0.99) | 0.004 | 0.98 (0.45-2.15) | 0.96 |
- Citation: Kushiyama A, Kikuchi T, Tanaka K, Tahara T, Takao T, Onishi Y, Yoshida Y, Kawazu S, Iwamoto Y. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1. World J Diabetes 2016; 7(11): 230-238
- URL: https://www.wjgnet.com/1948-9358/full/v7/i11/230.htm
- DOI: https://dx.doi.org/10.4239/wjd.v7.i11.230